1 Min Read
Oct 18 (Reuters) - Johnson & Johnson reported a 4.2 percent increase in quarterly revenue, fueled by strong sales in its prescription drugs business.
The company's net earnings rose to $4.27 billion, or $1.53 per share, in the third quarter, from $3.36 billion, or $1.20 per share, a year earlier.
Sales rose to $17.82 billion from $17.10 billion.
Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila